
    
      The investigators will be administering oral high dose interval vitamin D3 concurrently when
      participants with inflammatory bowel disease (IBD) are receiving biologic therapy every 4-8
      weeks. The investigators will collect additional bloodwork when participants are getting
      clinical labwork in order to assess markers of bone health and inflammation in response to
      vitamin D treatment. The investigators will serially assess with questionnaires associated
      measures, including dietary vitamin D and calcium intake, sunlight exposure, physical
      activity, fracture history, IBD disease activity, and overall health.
    
  